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Characterization of embryonic stem cell-
differentiated fibroblasts as mesenchymal
stem cells with robust expansion capacity
and attenuated innate immunity
William D’Angelo, Bohan Chen, Chandan Gurung and Yan-Lin Guo*
Abstract
Background: Mesenchymal stem cells (MSCs) isolated from adult tissues (Ad-MSCs) have shown great promise for
use in regenerative medicine. However, their poor in vitro expansion capacity and tissue scarcity have been major
limitations. In this study, we demonstrate that mouse embryonic stem cells (mESCs) can differentiate into cells with
MSC properties.
Methods: Using previously established methods that characterize Ad-MSCs, we analyzed mESC-differentiated
fibroblasts (mESC-FBs), including plastic adherence, clonogenic growth, MSC marker expression, tri-lineage
differentiation potential, and the capacity to express immunomodulators.
Results: Although previously characterized as mESC-differentiated fibroblasts (mESC-FBs), these cells exhibit major
properties of Ad-MSCs. However, mESC-FBs also display unique features inherited from ESCs, including robust
expansion capacity, senescence resistance, and attenuated innate immunity. In particular, mESC-FBs are insensitive
to bacterial endotoxin (lipopolysaccharide, LPS) and do not express LPS-induced inflammatory molecules, in
contrast to bone marrow (BM)-MSCs. We further demonstrate that mESC-FBs are resistant to the cytotoxicity
associated with inflammatory cytokines, bacterial endotoxins (LPS and heat-killed bacteria), and macrophage-
mediated inflammation.
Conclusions: While it remains to be determined how the unique properties of mESC-FBs will affect their
immunoregulatory activity under an in vivo condition, our findings demonstrate that ESCs could be used as an
alternative source to generate a new class of ESC-MSCs with unique features potentially useful in regenerative
medicine.
Keywords: Embryonic stem cells, Mesenchymal stem cells, Differentiation, Cell cycle, Senescence,
Immunosuppression, Inflammatory cytokines, Tissue regeneration
Background
Mesenchymal stem cells (MSCs) isolated from adult tissues
(Ad-MSCs) have rapidly advanced to clinical application
due to their defined differentiation potential (typically to os-
teocytes, chondrocytes, and adipocytes) and their ability to
secrete immunomodulators and trophic growth factors that
repress inflammation and promote tissue regeneration in
the host [1–3]. However, limited availability, low expansion
capacity, and significant donor-dependent variations have
been the major limitations for their therapeutic application
[1, 4]. On the other hand, embryonic stem cells (ESCs) have
greater potential to differentiate into a wide variety of cell
types and have unlimited expansion capacity [5], but gener-
ating clinically usable cells from ESCs is a task facing many
biological and technical challenges [6], including uncer-
tainty about the physiology, maturity, and functionality of
in vitro ESC-differentiated cells (ESC-DCs) owing to their
dramatically different routes of differentiation from natur-
ally differentiated somatic cells.
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The underdeveloped innate immunity in ESCs suggests
that “innate immunity,” as classically defined in somatic
cells, is not (at least not completely) innate to ESCs, but is
acquired by somatic cells during differentiation, as we
have demonstrated in mouse ESC (mESC) differentiation
to fibroblasts (mESC-FBs) [7–9]. FBs are highly responsive
to various immune stimuli and are a major tissue cell type
responsible for maintaining tissue immunity [10, 11].
Using mESC-FBs as a model system, we investigated in-
nate immunity development during in vitro differentiation
and demonstrated that mESC-FBs acquired the ability to
express IFNβ and inflammatory cytokines in response to
viral stimuli and TNFα, respectively; however, they have
substantially lower levels of responsiveness than naturally
differentiated FBs [7–9]. Together with similar results
found in other types of ESC-DCs [12–16], our findings
demonstrated that innate immunity is developmentally
regulated, but the commonly used in vitro differentiation
methods can only partially promote this development.
Originally isolated and characterized as FB-like multipo-
tent cells from bone marrow [2], bone marrow-MSCs
(BM-MSCs) can differentiate into adipocytes, osteocytes, or
chondrocytes (known as tri-lineage differentiation). This
property is regarded as the basis of using BM-MSCs in tis-
sue repair and regeneration, but it is now increasingly clear
that their therapeutic effects are largely attributable to their
ability to secrete immunoregulators and trophic factors
(collectively referred to as “bioactive factors”), which modu-
late host immunity and promote tissue healing via para-
crine signaling [3]. MSCs have now been isolated from a
variety of adult and fetal tissues. Interestingly, studies have
shown that MSCs share many similarities with FBs, for in-
stance in morphology and cell-surface markers. In fact,
BM-MSCs were first isolated based on their
plastic-adherence property originally noted in FBs. Further-
more, immunoregulatory properties similar to MSCs have
been reported in adult human FBs [17, 18]. While the exact
relationship between FBs and MSCs remains to be defined,
existing evidence suggests that they may represent subtypes
of the same (or similar) cells with overlapping functions
[17, 19, 20]. While using mESC-FBs as a model to study in-
nate immunity development, we have noticed that they dis-
play the major characteristics of Ad-MSCs. In this study,
we demonstrate that mESC-FBs (as we previously desig-
nated them) can also be classified as mESC-MSCs. Al-
though ESC-MSCs have been differentiated from both
mESCs and human ESC (hESCs) as well as iPSCs and com-
pared with Ad-MSCs in terms of basic MSC properties and
therapeutic potential [21], they are not nearly as
well-characterized as Ad-MSCs. In particular, their attenu-
ated innate immunity inherited from ESCs, together with
their robust expansion capacity and resistance to senes-
cence, can classify ESC-MSCs as a new type of MSCs with
valuable attributes for therapeutic application.
Methods
Cells and cell culture
mESC-FBs were differentiated from D3 and DBA252
mESCs through a retinoic acid (RA)-induced differenti-
ation protocol and purified based on their rapid adher-
ence to an uncoated cell culture dish as described in our
published studies [7, 8]. Since mESC-FBs differentiated
from D3 and DBA mESCs were similar in all properties
tested, the experiments in this study were mainly per-
formed with mESC-FBs differentiated from D3 cells and
some key experiments were confirmed with the cells dif-
ferentiated from DBA cells. mESC-FBs from passages 5–
35 were used for this study. Primary MSCs from mouse
bone marrow (BM-MSCs) were obtained from an
NIH-funded research center at The Scripps Research In-
stitute – Scripps Florida, Department of Molecular
Therapeutics [22]. Cells from passage 2 to 5 were used
for the experiments. RAW264.7 cells (RAW, a murine
macrophage cell line) were obtained from ATCC (Ma-
nassas, VA, USA). All cells were cultured in DMEM with
10% fetal bovine serum (FBS) and 100 units/ml penicillin
and 100 μg/ml streptomycin and maintained at 37 °C in
a humidified incubator with 5% CO2.
Preparation of conditioned medium and heat killed
bacteria and cell treatment
To prepare conditioned medium (CM), RAW cells were
treated with lipopolysaccharide (LPS) (1 μg/ml, isolated
from E.coli O111:B4, Sigma) for 4 h. The medium was
removed and cells were thoroughly washed with PBS
and then cultured in fresh medium for an additional
24 h. The CM was collected and designated as LPS-CM.
CM prepared from RAW cells without treatment was
used as a control (CM). Heat-killed E. coli (O157:H7,
ATCC) (HKE) were prepared by heating bacteria in PBS
at 80 °C for 1 h [23]. mESC-FBs and BM-MSCs were
treated with CM or LPS-CM (diluted with fresh medium
containing 2% FBS at 1:1 ratio), HKE (at a ratio of 200:1
bacteria to mESC-FBs or BM-MSCs), LPS (1 μg/ml),
TNFα, IL-1β, or IFNγ (20 ng/ml, Peprotech, Rocky Hill,
NJ, USA). For cytotoxicity analysis, cells were treated in
DMEM containing 2% FBS. For all other experiments,
cells were treated in DMEM containing 10% FBS under
the conditions as specified in the individual experiments.
Analysis of cell proliferation, viability, clonal growth, and
senescence
Cell proliferation and viability were determined by tolui-
dine blue (TB) staining as previously described [24]. The
absorbance at 630 nm of stained cells was measured
with a Biotek ELx800 microtiter plate reader. The ab-
sorbance values were used as an indirect measurement of
cell number, or the numbers of cells were counted from
photographed images of TB stained cells as described in
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individual experiments. For clonal growth analysis,
mESC-FBs were plated in a six-well cell culture dish at
low density (~ 400 cells/well) and allowed to grow for
2 weeks. The colonies derived from single cells were fixed
and stained with TB for morphological analysis or further
propagated to determine cell growth rate. Senescence was
determined by morphological criteria and by cellular/bio-
chemical marker analysis as previously described [24].
Briefly, mESC-FBs and BM-MSCs were plated at ~ 50%
confluence and cultured for 7 days. The cells were ana-
lyzed with a β-galactosidase (β-Gal) senescence detecting
kit (Sigma-Aldrich, St. Louis, MO, USA) and by the ex-
pression levels of senescence markers, p21 and p16.
Tri-lineage differentiation of mESC-FBs and detection of
adipocytes, osteocytes, and chondrocytes
The potential of mESC-FBs to differentiate to adipocytes,
osteocytes, and chondrocytes was assessed by a spontan-
eous differentiation protocol. mESC-FBs were seeded at
60–70% confluence and continuously cultured in a dish up
to 4 weeks without splitting, during which cells underwent
spontaneous differentiation. Many cells in the monolayer
developed oil droplets, a characteristic of adipocytes that
can be visually detected in live cells. For further analysis,
the cells were fixed and stained with 0.5% Oil-Red O, 2%
Alizarin Red S, or 0.1% Safranin O (Sigma-Aldrich) to stain
adipocytes, osteocytes, or chondrocytes, respectively, ac-
cording to published protocols [22, 25]. The differentiated
cells were further assessed by the expression of adipocyte,
osteocyte, and chondrocyte markers with RT-qPCR.
Real-time quantitative polymerase chain reaction (RT-
qPCR)
Total RNA was extracted using TRI-reagent (Sigma-Al-
drich). cDNA was prepared using moloney murine
leukemia virus reverse transcriptase (Promega, Madison,
WI, USA). RT-qPCR was performed using SYBR green
ready mix (Bio-Rad) on a MX3000P RT-PCR system (Agi-
lent, Santa Clara, CA, USA). The mRNA levels from
RT-qPCR were calculated using the comparative Ct
method [26]. β-actin was used as a calibrator for the calcu-
lation of relative mRNA levels of the tested genes. As speci-
fied in individual experiments, the mRNA levels were
either expressed as fold-activation, where the values in the
controls were designated as 1, or expressed as relative levels
normalized to β-actin (designated as 1). The sequences of
the primer sets utilized for RT-qPCR are listed in Table 1.
Protein analysis by flow cytometry
Protein analysis by flow cytometry was performed ac-
cording to our published method [27]. Briefly, fixed cells
were incubated with the antibodies against the specific
proteins to be analyzed, including antibodies for iNOS,
COX2 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), CD29, CD44, CD105, and CD31 (BD Biosciences,
Billerica, MA, USA) as specified in individual experi-
ments. The cells were then incubated with secondary
antibodies conjugated with FITC (fluorescein isothio-
cyanate) and examined with an Accuri C6 flow cyt-
ometer (BD Biosciences, San Jose, CA, USA). The
fluorescence intensity, which correlates with the protein
level, was determined with the CFlow software [27].
Immunocytochemistry
Immunostaining was performed according to the method
previously described [7]. The cellular location of NFκB was
Table 1 The primer sequences used for RT-qPCR
Gene Forward primer (5′–3′) Reverse primer (5′–3′)
β-actin CATGTACGTAGCCATCCAGGC CTCTTTGATGTCACGCACGAT
Runx2 GCCCAGGCGTATTTCAGA TGCCTGGCTCTTCTTACTGAG
OCN CTGACCTCACAGATGCCAAG GTAGCGCCGGAGTCTGTT
SOX9 AGTACCCGCATCTGCACAAC ACGAAGGGTCTCTTCTCGCT
Col2α1 GGGTCACAGAGGTTACCCAG ACCAGGGGAACCACTCTCAC
PPARγ GGAAGACCACTCGCATTCCTT GTAATCAGCAACCATTGGGTCA
C/EBPα CAAGAACAGCAACGAGTACCG GTCACTGGTCAACTCCAGCAC
CD106 CCAAATCCACGCTTGTGTTGA GGAATGAGTAGACCTCCACCT
CD105 AGGGGTGAGGTGACGTTTAC GTGCCATTTTGCTTGGATGC
CD73 CCTGCACACAAACGACGTG CTGGTCTCCGGCATCCAAAA
CD29 ATGCCAAATCTTGCGGAGAAT TTTGCTGCGATTGGTGACATT
CD44 TCGATTTGAATGTAACCTGCCG CAGTCCGGGAGATACTGTAGC
CD31 TGCACCCATCACTTACCACC CTTCATCCACCGGGGCTATC
CD34 CTGGGTAGCTCTCTGCCTGAT TGGTAGGAACTGATGGGGATATT
TNFα CAGGCGGTGCCTATGTCTC CGATCACCCCGAAGTTCAGTAG
MHCI CCTTGGAGCTGCAATAGTC CTGGGAGAGACAGATCAGAG
MHCII CAACCGTGACTATTCCTTCC CTCAGGTTCCCAGTGTTTC
iNOS CAGCACAGGAAATGTTTCAGC TAGCCAGCGTACCGGATGA
CyclinD1 CAGAAGTGCGAAGAGGAGGTC TCATCTTAGAGGCCACGAACAT
CyclinE AATTGGGGCAATAGAGAAGAGGT TGGAGCTTATAGACTTCGCACA
CyclinA ACATTCACACGTACCTTAGGGA CATAGCAGCCGTGCCTACA
CyclinB CTCAGGGTCACTAGGAACACG AGCTCTTCGCTGACTTTATTACC
P16 CGCAGGTTCTTGGTCACTGT TGTTCACGAAAGCCAGAGCG
P21 CGAGAACGGTGGAACTTTGAC CAGGGCTCAGGTAGACCTTG
VEGF GGAGATCCTTCGAGGAGCACT GGCGATTTAGCAGCAGATATAA
SCF CCCTGAAGACTCGGGCCTA CAATTACAAGCGAAATGAGAGCC
TGFβ ATCCTGTCCAAACTAAGGCTCG ACCTCTTTAGCATAGTAGTCCGC
PDGF CATCCGCTCCTTTGATGATCTT GTGCTCGGGTCATGTTCAAGT
HGF ATGTGGGGGACCAAACTTCTG GGATGGCGACATGAAGCAG
SDF TGCATCAGTGACGGTAAACCA CACAGTTTGGAGTGTTGAGGAT
CTGF GGGCCTCTTCTGCGATTTC ATCCAGGCAAGTGCATTGGTA
bFGF GCGACCCACACGTCAAACTA CCGTCCATCTTCCTTCATAGC
ICAM1 GGCATTGTTCTCTAATGTCTCCG GCTCCAGGTATATCCGAGCTTC
IL6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC
IL1α TCTATGATGCAAGCTATGGCTCA CGGCTCTCCTTGAAGGTGA
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determined with its specific antibodies against RelA subunit
(Santa Cruz Biotechnology). The cells were examined under
an LSM 510 laser-scanning confocal microscope (Zeiss).
Statistical analysis
For statistical analysis, data are presented as the
mean + SD derived either from three independent ex-
periments or from a representative experiment per-
formed in triplicate that was performed at least twice
with similar results. Statistical analysis was performed
using a two-tailed and paired Student’s t test. Differences
are considered statistically significant when p < 0.05.
Results
Tri-lineage differentiation of mESC-FBs
In our previous studies, we have comparatively analyzed
mESC-FBs with mouse embryonic fibroblasts. They
show very similar morphology and express common
markers of fibroblasts [7–9]. In addition to the complete
loss of ESC morphology, the expression level of the plur-
ipotency marker genes Oct4, Nanog, and Sox2 in
mESC-FBs is less than 1% of that expressed in mESCs
(data not shown). The first indication suggesting that
mESC-FBs have the properties of MSCs was their differ-
entiation to adipocytes. As shown in Fig. 1a, mESC-FBs
showed typical morphology of FBs and MSCs at
sub-confluence (Fig. 1a, 2d). When mESC-FBs were con-
tinually cultured, they grew into a compact cell layer and
underwent spontaneous differentiation after prolonged
culture without passaging (Fig. 1a, 5d). Oil droplets
began to appear in some cells around 2 weeks of differ-
entiation and the number and size of these structures in-
creased along with continued culture for up to 4 weeks
(Fig. 1a, 4w). These droplets stained heavily with Oil Red
O, which is used to identify adipocytes. The differenti-
ated cell layer also contained cells that stained positively
with Alizarin Red S and Safranin O (Fig. 1a), two chem-
ical agents commonly used to identify osteogenic and
chondrogenic differentiation, respectively. The identities
of these cells were confirmed by the expression of their
marker genes or transcription factors that promote their
differentiation (Fig. 1b, Runx2/OCN for osteocytes,
Sox9/COL2A1 for chondrocytes, and PPARγ/C/EBPα
for adipocytes). These results demonstrate that
mESC-FBs have the potential for tri-lineage differenti-
ation shown by Ad-MSCs.
mESC-FBs express common MSC markers and have clonal
growth capacity
While there are no definitive markers that can reliably
define MSCs, they are generally characterized by the lack
of hematopoietic and endothelial markers and positive
expression of a panel of surface markers [20, 28]. We tested
markers that are commonly used to identify Ad-MSCs,
including CD29, CD44, CD105, and CD106. All of them
were detected in mESC-FBs with a very similar expression
pattern to BM-MSCs at the mRNA level while CD31 and
CD34 (endothelial and hematopoietic markers, respectively)
were not detected (Fig. 2a). The results were confirmed by
the expression of selected markers at the protein level by
flow cytometry (Fig. 2b). When seeded at very low density,
single mESC-FBs grew into individual colonies of FB-like
clonogenic progeny (known as colony-forming unit FBs).
This assay was originally used to determine the number of
BM-MSCs within a given cell population of bone marrow
cells and is considered to be a major parameter of
self-renewal capacity of MSCs [29]. Single mESC-FBs grew
into individual colonies of various sizes (Fig. 2c, inset, a).
The cells within a colony have fairly uniform morphology,
as shown in a representative colony (Fig. 2c, inset, b), al-
though cells from different colonies showed certain degrees
of differences in morphology (data not shown) and growth
rate (Fig. 2c, graph).
mESC-FBs can express immune modulators in response to
inflammatory cytokines and have low levels of expression
of the major histocompatibility complexes (MHCs)
In response to immune and inflammatory stimuli, MSCs
produce cytokines and immune modulators, which
modulate tissue immunity and activities of immune cells
[1, 3]. We evaluated the response of mESC-FBs to IFNγ,
TNFα, and IL1β, three cytokines known to activate
BM-MSCs [30]. Each cytokine alone slightly stimulated
(two- to fourfold) the expression of IL6, ICAM1, and
TNFα (common effectors of inflammatory responses),
but the combination of IFNγ with TNFα, and to a lesser
extent, with IL1β had significant synergistic effects in
stimulating the expression of these molecules (Fig. 3a).
Similar results were observed for inducible nitric oxide
synthase (iNOS) and cyclooxygenase-2 (COX2) as deter-
mined at both mRNA and protein levels in mESC-FBs
(Fig. 3b, c), two key molecules in mediating the immu-
nomodulatory effects of mouse BM-MSCs [21, 30].
The immune tolerance of BM-MSCs in cell transplant
is, in part, due to the low level expression of MHCs that
allow them to avoid the host’s immune rejection [1, 31].
ESCs do not express MHCs and co-stimulatory mole-
cules [32, 33] and are considered to be immune privi-
leged [34]. In a direct comparison, our RT-qPCR
analysis revealed that mESC-FBs expressed about 10
times lower levels of MHC I than BM-MSCs, while
MHC II was barely detected (Fig. 3d). There were no
significant changes in the expression levels of MHC I
and MHC II between mESCs and mESC-FBs, indicating
that in vitro differentiation methods used for the gener-
ation of mESC-FBs did not result in an apparent upregu-
lation of MHCs.
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mESC-FBs have robust growth potential and are
senescence resistant
While mESC-FBs display the general properties of MSCs,
they have some distinctive features. One of the most not-
able properties of mESC-FBs is their robust growth poten-
tial and expansion capacity. When subcultured every 3–
4 days, mESC-FBs can be continuously propagated for up
to 50 passages, while BM-MSCs typically can propagate
for only 5–10 passages [35]. In our case, BM-MSCs began
to enter senescence after passage 4. As shown in Fig. 4a,
mESC-FBs grew into a compact monolayer when cultured
for 7 days, with very few cells showing a senescent pheno-
type. Under the same conditions, BM-MSCs (p4) began to
enter senescence and showed typical characteristics of
senescent cells: large, flattened cell bodies and positive
staining for β-Gal activity [24]. At the molecular level,
BM-MSCs expressed much higher levels of cell cycle in-
hibitors (p16 and p21), which are also commonly used as
markers of senescence [24]. Conversely, mESC-FBs
expressed substantially higher levels of cyclin A and cyclin
B (Fig. 4b), two cyclins which are highly expressed in
mESCs and are responsible for their rapid cell prolifera-
tion [24, 36]. These results suggest that mESC-FBs partly
retained the higher proliferation capacity of mESCs.
MSCs produce many trophic factors that promote
angiogenesis, cell survival, and wound healing [1].
Fig. 1 Tri-lineage differentiation of mESC-FBs. Cells were differentiated for up to 4 weeks and were analyzed at the times indicated. a Upper
panels: 2d, morphology of individual cells at low density after seeding for 2 days; 5d, monolayer formed from cells cultured for 5 days; 4w, oil
droplets formed in adipocytes after the cells were cultured for 4 weeks. Bottom panels: cells differentiated for 3 weeks were fixed and stained
with the indicated dyes. The cells were photographed under a phase contrast microscope after they were stained with TB (2d and 5d), Oil Red O,
Alizarin Red, or Safranin O. The cells shown in 4w panel were live cells without staining. Scale bar = 100 μm. b Analysis of tri-lineage marker
expression by RT-qPCR in the cells differentiated for 10 days and 20 days. The values in the control group represent the mRNA levels in cells
before differentiation. Values are mean ± SD of an experiment performed in triplicate and repeated three times with similar results. *p < 0.05,
compared with respective controls (Con)
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RT-qPCR analysis revealed that several trophic factors
commonly expressed in BM-MSCs were detected in
mESC-FBs, but the expression levels of individual factors
varied somewhat in BM-MSCs and mESC-FBs (Fig. 4c).
Notably, connective tissue growth factor (CTGF), a
matricellular protein that has important roles in cell ad-
hesion, proliferation, and tissue repair [37], was
expressed much more highly in BM-MSCs than in
mESC-FBs. Conversely, stromal cell-derived factor-1
(SDF-1), a chemokine that regulates cell migration and
attracts immune cells to the inflammatory site [38], was
expressed about 10 times higher in mESC-FBs than in
BM-MSCs (Fig. 4c)
mESC-FBs lack response to LPS
We have previously reported that mESCs lack response
to TNFα, IL1β, and LPS [9]. Here we compared
mESC-FBs with BM-MSCs. Activation of NFκB tran-
scription factor is essential in mediating the effects of
the aforementioned agents. In unstimulated cells, NFκB
is retained in the cytoplasm by inhibitor of NFκB protein
(IκB). Upon cell activation, NFκB is translocated to the
nucleus where it activates transcription of target genes.
Therefore, nuclear translocation is commonly used as an
indicator of NFκB activation. As shown in Fig. 5a, NFκB
was detected in the cytoplasm of mESC-FBs and
BM-MSCs as expected in control cells. Both LPS and
TNFα induced NFκB nuclear translocation in BM-MSCs
(Fig. 5a, upper panels), but only TNFα, not LPS, induced
NFκB nuclear translocation in mESC-FBs (Fig. 5a, lower
panels). We further analyzed the responsiveness of
BM-MSCs and mESC-FBs to LPS by determining the ex-
pression of TNFα, IL6, and ICAM1, three genes that are
under the transcriptional control of NFκB [39, 40]. Con-
sistent with NFκB nuclear translocation experiments,
LPS increased the expression of all three genes in
BM-MSCs, but it did not significantly alter their expres-
sion level in mESC-FBs at any times tested (Fig. 5b).
Therefore, the lack of response to LPS is a distinctive
feature of mESC-FBs from BM-MSCs. LPS-activated sig-
naling occurs via its interaction with TLR4 at the cell
surface. Through a series of signaling events, activated
TLR4 leads to NFκB activation [41]. We demonstrated
that TLR4 was not detected in mESCs and differenti-
ation could not result in its expression at the protein
level [9], which explains the failure of LPS to activate
NFκB and stimulate the expression of inflammatory
molecules in mESC-FBs.
mESC-FBs are less sensitive to cytotoxicity of
inflammatory cytokines than BM-MSCs
To determine the physiological implications of lacking
response to LPS in mESC-FBs, we tested the effects of
several inflammatory conditions on the viability of
mESC-FBs. It is known that LPS-induced inflammatory
responses can cause serious cell and tissue damage if un-
regulated. Its cytotoxic effect can be significantly poten-
tiated by IFNγ and the combination of LPS and IFNγ
causes cell death of several types of cells [42, 43]. We
treated mESC-FBs and BM-MSCs with LPS in the pres-
ence or absence of IFNγ. Neither LPS nor IFNγ alone
Fig. 2 MSC marker expression and clonal growth of mESC-FBs. a
Comparative analysis of MSC marker expression by RT-qPCR in
mESC-FBs and BM-MSCs. Results are mean ± SD of three
independent experiments. b Flow cytometry analysis of selected
MSC markers in mESC-FBs. Con represent cells stained with isotype
control antibodies. Results are representatives of three independent
experiments. c Clonal growth of mESC-FBs. The cells in the plate
were photographed with a digital camera (a) or cells in a single
colony photographed under a phase contrast microscope (100×)
after they were stained with TB. The graph illustrates growth curves
of three representative clones. Values are mean ± SD of an
experiment performed in triplicate and repeated two times with
similar results
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caused detectable cell death within a period of 4 days of
treatment (data not shown), but their combination caused
apparent toxicity in BM-MSCs, but not in mESC-FBs
(Fig. 6a). The tolerance of mESC-FBs to bacterial toxicity
was further illustrated by their insensitivity to HKE, which
effectively killed BM-MSCs without apparent effect on
mESC-FBs (Fig. 6a). To further compare the effects of an
inflammatory environment on mESC-FBs and BM-MSCs,
we used an in vitro macrophage-induced inflammation
model, which is based on the fact that these innate im-
mune cells express large amounts of cytokines when acti-
vated by immunostimuli such as LPS [44, 45]. In this
model, conditioned medium was collected from untreated
and LPS-stimulated RAW cells (designated as CM and
LPS-CM, respectively), which contained various inflam-
matory cytokines and immunomodulators secreted by
RAW cells. Both CM and LPS-CM showed significant
cytotoxicity to BM-MSCs, causing more than 50% cell
death after a 4-day treatment. However, only LPS-CM,
not CM, showed an apparent but much lower cytotoxic
effect on mESC-FBs than on BM-MSCs (Fig. 6a). Quanti-
tative analysis of cytotoxicity caused by HKE and RAW
cell conditioned medium, as determined by the number of
viable cells after treatments, is shown in Fig. 6b.
To obtain further insight into the molecules respon-
sible for the cytotoxic effects of RAW cell conditioned
medium, we examined the expression of TNFα, IL1α,
and IL6 in RAW cells that were used for preparing CM
and LPS-CM since these cytokines are implicated in me-
diating the cytotoxicity of RAW cells [46]. As expected,
the expression of all three genes was stimulated by LPS
in RAW cells, with TNFα being expressed at the highest
level (Fig. 6c, right panel). In comparison, the basal
levels of TNFα and IL1α were expressed at substantially
higher levels in unstimulated RAW cells (cells used to
prepare CM) than in mESC-FBs. These results could ex-
plain the cytotoxic effect of CM on BM-MSCs (as shown
in Fig. 6a, b) since the cytotoxic effect of RAW cells is,
at least partly, attributed to TNFα and IL1 [47, 48],
which can be potentiated by LPS [45]. While we do not
know what other molecules in the conditioned medium
from RAW cells or HKE might contribute to the
Fig. 3 Immunologic properties of mESC-FBs. a Expression of
immunomodulators induced by inflammatory cytokines. Cells were
treated for 24 h with indicated cytokines, alone or in combination.
The expression levels of IL6, TNFα and ICAM1 were determined by
RT-qPCR analysis. b, c Analysis of IFNγ- and TNFα-induced iNOS and
COX2 expression by RT-qPCR (b) and flow cytometry (c). d
Comparative analysis of MHC expression in BM-MSCs, mESCs and
mESC-FBs by RT-qPCR. Values in RT-PCR analysis are mean ± SD of
data from three independent experiments. *p < 0.05, a, b, compared
with respective controls (Con); d compared with ESC. The results in
flow cytometry are representative experiments performed three
times with similar results
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observed cytotoxic effects, our results clearly demon-
strate that mESC-FBs are less sensitive than BM-MSCs
to cytotoxicity caused by inflammatory conditions.
Discussion
Ad-MSCs, especially BM-MSCs, have been at the forefront
of developing stem cell-based therapies, but their limited
availability and poor expansion capacity make them
practically difficult to be used as an off-the-shelf product
for therapeutic application. The generation of MSCs from
both hESCs and mESCs with basic properties similar to
Ad-MSCs has demonstrated the feasibility of using ESCs as
an alternative source to generate MSCs [21]. The
large-scale production of ESC-MSCs may overcome some
limitations encountered with Ad-MSCs and offer additional
valuable features for their potential therapeutic application.
To date, ESC-MSCs have been mainly characterized
according to the basic criteria set for Ad-MSCs, but the
unique properties of ESC-MSCs have not been
well-understood [21]. The significantly higher expansion
capacity of ESC-MSCs compared with BM-MSCs can be
rationally explained by the high activity of telomerase in
ESC-MSCs and the lack of such activity in BM-MSCs
[35, 49–51]. The high levels of cyclins A and B and the
Fig. 4 Analysis of senescence, cell cycle proteins, growth factors,
and chemokines. a Senescence analysis of mESC-FBs and BM-MSCs
cultured for 7 days. Senescent cells were identified by β-Gal activity
staining (blue color) and photographed under a phase-contrast
microscope. Scale bar = 100 μm. b, c RT-qPCR analysis of cell cycle
proteins (b), growth factors, and chemokines (c). The mRNA levels of
the tested genes were determined from untreated mESC-FBs and
BM-MSCs. Results are means ± SD of three to five independent
experiments. *p < 0.05, compared between two cell types
Fig. 5 mESC-FBs do not respond to LPS. a BM-MSCs (upper panels)
and mESC-FBs (bottom panels) were treated with LPS for 60 min or
TNFα for 15 min, or left untreated (Con). The cellular location of
NFκB was detected with an antibody against NFκB under a
fluorescence microscope. Scale bar = 50 μm. b Cells were treated
with LPS for the indicated time. The expression of TNFα, ICAM1, and
IL6 was determined by RT-qPCR. Con represents cells without any
treatment. Values are mean ± SD of samples from three independent
experiments. *p < 0.05, compared with respective controls (Con)
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low levels of cell cycle inhibitors demonstrated in this
study provide additional molecular basis for the higher
cell proliferation rate and senescence resistance in
mESC-MSCs. In addition to the poor expansion capacity
of BM-MSCs, rapid senescence as we have shown here
by in vitro cell culture is another major shortfall of these
cells that contributes to their transient therapeutic effect
due to rapid senescence shortly after implantation [52].
Therefore, the high expansion capacity, high prolifera-
tion rate, senescence resistance, and low levels of MHC
expression in ESC-MSCs could be highly desirable fea-
tures with respect to therapeutic application.
The idea of using MSCs for therapeutic application
was originally driven by their tri-lineage differentiation
potential to repair damaged tissues. However, it is now
increasingly clear that their therapeutic effects are
largely attributable to their ability to secrete immuno-
modulators and trophic factors (collectively referred to
as “bioactive factors”), which promote tissue healing and
repair [1, 3]. While the expression levels of trophic fac-
tors in mESC-FBs were somewhat different from
BM-MSCs, they showed a rather similar expression pro-
file of immunomodulators in response to TNFα and
IFNγ to BM-MSCs, including TNFα, IL6, iNOS, and
Fig. 6 mESC-FBs are less sensitive to cytotoxicity of inflammatory conditions than BM-MSCs. a mESC-FBs and BM-MSCs were cultured under the
indicated conditions for 4 days. The cells were fixed and stained with TB and photographed under a phase-contrast microscope, scale bar =
100 μm. b Quantitative analysis of relative numbers of cells under the indicated treatment conditions. Values are mean ± SD of cell numbers
counted in three fields from a representative experiment under the indicated treatment conditions as described in a. *p < 0.05, compared with
respective controls (Con). c RT-qPCR analysis of inflammatory cytokine expression in untreated mESC-FBs and RAW cells (left panel) and in LPS-
stimulated RAW cells (right panel). Values are mean ± SD of results from three independent experiments. *p < 0.05, left panel compared between
two cell types; right panel, compared with respective controls (Con)
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COX-2 [30], which are among the best-characterized
molecules responsible for the immunoregulatory effects
of BM-MSCs [21, 30, 53]. These data suggest that
mESC-FBs and BM-MSCs share basic immunoproper-
ties. However, the immunomodulatory activity of
Ad-MSCs on host immunity has become an increasingly
complex issue. Studies have shown that the therapeutic
effects of Ad-MSCs vary depending on their tissue origin
and can be affected by the nature of the immunostimuli
that lead to their activation [2, 3]. It has been proposed
that LPS and polyIC could stimulate BM-MSCs to ex-
press different sets of immunomodulators, thereby pro-
moting BM-MSCs to adopt either “pro- or
anti-inflammatory phenotypes” [54]. However, inconsist-
ent and even conflicting results have been reported in
other studies [54–57]. The immunological behaviors of
Ad-MSCs seem to be rather “elusive” [58]. The lack of
response to LPS demonstrated in this study represents a
distinctive feature of mESC-MSCs. It is conceivable that
their immunobehavior and therapeutic value could sig-
nificantly differ from BM-MSCs, which is an important
subject that will need to be investigated with dedicated
future studies.
The biological implications of underdeveloped innate
immunity in ESCs can be viewed from different perspec-
tives of stem cell biology, developmental biology, and
immunology (reviewed in [59, 60]). The attenuated in-
nate immunity in mESC-FBs is inherited from mESCs.
This is not surprising considering the fact that
mESC-FBs are generated by in vitro differentiation,
which cannot faithfully recapitulate the differentiation
process in vivo. As such, the attenuated innate immunity
in mESC-FBs (or other types of ESC-differentiated cells
for that matter) could be a deficiency associated with in
vitro differentiation, but it could be a desirable feature
for their therapeutic application. The inflammatory re-
sponse has been viewed as a double-edged sword. On
the one hand, it is a mechanism that defends the organ-
ism against pathogenic invasion. On the other hand, it
causes various adverse effects when it is dysregulated,
such as cell cycle inhibition and even cell death of in-
fected tissues [61, 62]. From this perspective, the lack of
response to LPS, which is a property inherited from
mESCs [9], could allow mESC-FBs to survive better
under inflammatory conditions as demonstrated by our
in vitro experiments. In fact, mESCs, which also lack re-
sponse to TNFα [9], are insensitive to the cytotoxic ef-
fects of inflammatory stimuli that cause cell death of
BM-MSCs described in this study (unpublished re-
sults). However, it is also possible that this property
could compromise their immune suppressive ability. It
should be noted that previous studies have demonstrated
that both soluble mediators secreted by MSCs and direct
MSC interaction with immune cells, such as T cells,
contribute to their immunomodulatory effects [21].
While the current study has shown that ESC-FBs resem-
ble MSCs in producing inflammatory mediators,
whether or not they exhibit immune suppressive effects
on immune cells through cell-cell interaction is an im-
portant question that remains to be addressed. There-
fore, how the attenuated innate immunity affects the
fate, functionality, and therapeutic value of mESC-FBs is
a complex issue that needs to be further investigated by
in vitro studies and assessed under in vivo settings.
Conclusion
This study demonstrated that mESC-FBs can be classi-
fied as a new class of MSCs with general properties of
Ad-MSCs and additional unique features inherited from
ESCs. Their robust expansion capacity, resistance to sen-
escence, and tolerance to the cytotoxic effect of inflam-
matory cytokines could be desirable features for their
therapeutic application. How attenuated innate immun-
ity in ESC-MSCs will affect their immunoregulatory ac-
tivity under in vivo conditions remains to be
determined, but it is an attractive feature that could be
modulated during in vitro differentiation based on the
fact that innate immunity is developmentally regulated.
By controlling differentiation conditions, it is feasible to
develop a strategy that can generate ESC-MSCs with
high regenerative capacity and desirable immunoproper-
ties for therapeutic application. However, the immuno-
logical properties, especially whether ESC-MSCs show
immune suppressive effect on immune cells through
cell-cell interaction, will need to be further characterized
by in vitro and in vivo studies.
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